Trials / Completed
CompletedNCT02400788
Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
A Phase I/II Study in Combination of Resminostat and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Previously Untreated With Systemic Chemotherapy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 179 (actual)
- Sponsor
- Yakult Honsha Co., LTD · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Resminostat | |
| DRUG | Sorafenib |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2016-06-01
- Completion
- 2016-10-01
- First posted
- 2015-03-27
- Last updated
- 2018-01-16
Locations
12 sites across 2 countries: Japan, South Korea
Source: ClinicalTrials.gov record NCT02400788. Inclusion in this directory is not an endorsement.